Edition:
United Kingdom

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

1.52USD
5:37pm BST
Change (% chg)

$0.04 (+2.70%)
Prev Close
$1.48
Open
$1.47
Day's High
$1.57
Day's Low
$1.47
Volume
14,314
Avg. Vol
22,606
52-wk High
$5.46
52-wk Low
$1.12

Chart for

About

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortiso... (more)

Overall

Beta: --
Market Cap(Mil.): $26.02
Shares Outstanding(Mil.): 8.25
Dividend: --
Yield (%): --

Financials

  CTXR.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -2.01 -- --
ROI: -66.76 15.07 14.61
ROE: -66.76 16.59 16.33

BRIEF-Citius Pharmaceuticals To Sell Up To 1.4 Mln Shares Of Co's Common Stock

* CITIUS PHARMACEUTICALS - TO SELL OR OTHER DISPOSITION FROM TIME TO TIME OF UP TO 1.4 MILLION SHARES OF CO'S COMMON STOCK Source : https://bit.ly/2JdehV7 Further company coverage: (Reuters.Briefs@thomsonreuters.com)

20 Apr 2018

BRIEF-Citius Announces $2 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

06 Mar 2018

Earnings vs. Estimates